Bundamedik Tbk PT
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, medical tourism, and dental clinic services management consulting businesses. It al… Read more
Bundamedik Tbk PT (BMHS) - Net Assets
Latest net assets as of September 2025: Rp2.16 Trillion IDR
Based on the latest financial reports, Bundamedik Tbk PT (BMHS) has net assets worth Rp2.16 Trillion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp3.64 Trillion) and total liabilities (Rp1.48 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp2.16 Trillion |
| % of Total Assets | 59.29% |
| Annual Growth Rate | 26.17% |
| 5-Year Change | 104.6% |
| 10-Year Change | N/A |
| Growth Volatility | 23.37 |
Bundamedik Tbk PT - Net Assets Trend (2018–2024)
This chart illustrates how Bundamedik Tbk PT's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bundamedik Tbk PT (2018–2024)
The table below shows the annual net assets of Bundamedik Tbk PT from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp2.15 Trillion | +19.32% |
| 2023-12-31 | Rp1.80 Trillion | -0.45% |
| 2022-12-31 | Rp1.81 Trillion | +7.20% |
| 2021-12-31 | Rp1.69 Trillion | +60.69% |
| 2020-12-31 | Rp1.05 Trillion | +57.71% |
| 2019-12-31 | Rp665.59 Billion | +25.06% |
| 2018-12-31 | Rp532.23 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bundamedik Tbk PT's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32924838303400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp304.98 Billion | 17.80% |
| Common Stock | Rp172.07 Billion | 10.04% |
| Other Comprehensive Income | Rp679.76 Billion | 39.67% |
| Other Components | Rp556.68 Billion | 32.49% |
| Total Equity | Rp1.71 Trillion | 100.00% |
Bundamedik Tbk PT Competitors by Market Cap
The table below lists competitors of Bundamedik Tbk PT ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
$23.77 Million |
|
CULP INC. DL-05
F:CUZ
|
$23.78 Million |
|
Claranova SE
PA:CLA
|
$23.78 Million |
|
Jorjin Technologies
TWO:4980
|
$23.79 Million |
|
Ledlink Optics
TWO:5230
|
$23.76 Million |
|
Northumberland Bancorp
PINK:NUBC
|
$23.76 Million |
|
Willow Lane Acquisition Corp. Warrants
NASDAQ:WLACW
|
$23.76 Million |
|
Raven Property Group Limited
F:R4M
|
$23.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bundamedik Tbk PT's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,589,813,147,615 to 1,713,479,286,000, a change of 123,666,138,385 (7.8%).
- Net income of 11,943,515,000 contributed positively to equity growth.
- Dividend payments of 63,930,605,000 reduced retained earnings.
- Other comprehensive income decreased equity by 2,751,343,446.
- Other factors increased equity by 178,404,571,831.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp11.94 Billion | +0.7% |
| Dividends Paid | Rp63.93 Billion | -3.73% |
| Other Comprehensive Income | Rp-2.75 Billion | -0.16% |
| Other Changes | Rp178.40 Billion | +10.41% |
| Total Change | Rp- | 7.78% |
Book Value vs Market Value Analysis
This analysis compares Bundamedik Tbk PT's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.29x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Rp57.51 | Rp189.00 | x |
| 2019-12-31 | Rp72.42 | Rp189.00 | x |
| 2020-12-31 | Rp116.52 | Rp189.00 | x |
| 2021-12-31 | Rp181.32 | Rp189.00 | x |
| 2022-12-31 | Rp185.53 | Rp189.00 | x |
| 2023-12-31 | Rp184.79 | Rp189.00 | x |
| 2024-12-31 | Rp199.16 | Rp189.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bundamedik Tbk PT utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.77%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 2.01x
- Recent ROE (0.70%) is below the historical average (6.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 1.04% | 0.60% | 0.69x | 2.51x | Rp-44.35 Billion |
| 2019 | 5.06% | 3.25% | 0.69x | 2.26x | Rp-30.54 Billion |
| 2020 | 11.90% | 10.32% | 0.53x | 2.17x | Rp18.94 Billion |
| 2021 | 20.22% | 18.43% | 0.64x | 1.72x | Rp159.37 Billion |
| 2022 | 8.08% | 7.77% | 0.56x | 1.84x | Rp-30.68 Billion |
| 2023 | 0.47% | 0.50% | 0.48x | 1.94x | Rp-151.52 Billion |
| 2024 | 0.70% | 0.77% | 0.45x | 2.01x | Rp-159.40 Billion |
Industry Comparison
This section compares Bundamedik Tbk PT's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $4,067,508,675,954
- Average return on equity (ROE) among peers: 27.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bundamedik Tbk PT (BMHS) | Rp2.16 Trillion | 1.04% | 0.69x | $23.76 Million |
| Metro Healthcare Indonesia (CARE) | $3.30 Trillion | 0.18% | 0.28x | $411.41 Million |
| Medikaloka Hermina PT (HEAL) | $2.37 Trillion | 5.25% | 0.76x | $810.80 Million |
| Lippo Karawaci Tbk (LPKR) | $23.57 Trillion | -40.88% | 1.20x | $179.43 Million |
| Mitra Keluarga Karyasehat Tbk PT (MIKA) | $3.28 Trillion | 17.29% | 0.13x | $602.27 Million |
| PT Murni Sadar Tbk (MTMH) | $50.49 Billion | 4.95% | 14.96x | $27.98 Million |
| Famon Awal Bros Sedaya (PRAY) | $3.13 Trillion | 6.43% | 0.62x | $52.90 Million |
| Royal Prima PT (PRIM) | $722.89 Million | 252.77% | 36.50x | $3.23 Million |
| PT Charlie Hospital Semarang Tbk (RSCH) | $150.46 Billion | -0.74% | 0.03x | $11.66 Million |
| Kedoya Adyaraya Tbk PT (RSGK) | $751.16 Billion | 3.35% | 0.10x | $3.08 Million |